for educational and safety purposes
Every compound in the sci-wiki that affects gi tract; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
10 sourced · 0 reference
Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a range of bacterial infections, including urinary, respiratory, gastrointestinal, bone, and skin infections. It works by blocking bacterial enzymes needed to copy and repair DNA and is especially active against Gram-negative bacteria. First introduced by Bayer in the late 1980s, it appears on the World Health Organization list of essential medicines but now carries strong safety warnings and faces rising bacterial resistance.
Mebendazole is a benzimidazole anthelmintic medication used to treat infections caused by parasitic worms, particularly intestinal roundworms. Developed by Janssen Pharmaceutica and in use since the early 1970s, it appears on the World Health Organization's List of Essential Medicines. Because it is poorly absorbed from the gut, it acts mainly on intestinal parasites with few effects on the rest of the body [1], and it has more recently attracted research interest as a possible repurposed anticancer agent [2].
Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory medication of the aminosalicylate class used to treat inflammatory bowel disease. Chemically related to salicylic acid, it works locally on the lining of the intestine to reduce inflammation and is a mainstay of treatment for ulcerative colitis, where it is used both to bring on and to maintain remission. It is delivered in oral tablets and capsules designed to release the drug in the colon, as well as in rectal suppositories and enemas.
Omeprazole, introduced in the late 1980s as the first proton pump inhibitor, suppresses gastric acid by irreversibly binding the H+/K+-ATPase (the proton pump) on parietal cells, an elegant covalent mechanism that made it a foundation therapy for reflux, peptic ulcer, and Helicobacter pylori eradication. Research has since uncovered striking off-target biology: omeprazole is a ligand of the aryl hydrocarbon receptor, a property implicated both in protection against hyperoxic lung injury and in unwanted renal effects. By neutralizing the acidic tumor microenvironment and impairing lysosomal function, it and related proton pump inhibitors can chemosensitize resistant cancers, while the drug class also interferes with mycobacterial drug efflux, hinting at antitubercular potential. It appears on the World Health Organization Model List of Essential Medicines; long-term use warrants attention to nutrient absorption, the gut microbiome, and CYP2C19-mediated drug interactions.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist introduced in 1991 that blocks serotonin signaling in the gut and the brainstem vomiting center, making it a mainstay for chemotherapy, radiation, and postoperative nausea. Beyond antiemesis, its modulation of 5-HT3-gated neurotransmission has driven repurposing research; controlled trials found it reduced drinking in early-onset alcohol use disorder, with response predicted by serotonin transporter and 5-HT3 receptor genotype, positioning it as an early example of pharmacogenetically guided addiction treatment. It has also shown benefit in diarrhea-predominant irritable bowel syndrome by slowing colonic transit, and as an adjunct in schizophrenia it has been studied for effects on negative symptoms and cognition. Its principal safety consideration is dose-dependent QT-interval prolongation.
Orlistat is a weight-loss medication that works in the gut rather than the brain, reducing the amount of dietary fat the body absorbs. It belongs to the class of lipase inhibitors, blocking the enzymes that break down fat so that a portion of the fat eaten passes through undigested. Developed by Hoffmann-La Roche and approved in 1999, it is sold as the prescription product Xenical and, at a lower strength, as the over-the-counter product Alli, and it remains one of the few medicines specifically approved for long-term weight management.
Pantoprazole is a proton pump inhibitor (PPI) of the benzimidazole class used to reduce stomach acid. It works by irreversibly blocking the H+/K+ ATPase, the acid pump of the stomach's parietal cells, and is prescribed for conditions such as gastroesophageal reflux disease, erosive esophagitis, peptic ulcers, and acid-hypersecretory states. First marketed in the 1990s, it is available in oral and intravenous forms.
Ramosetron is a selective 5-HT3 receptor antagonist developed by Astellas Pharma and marketed mainly in Japan and parts of Asia. It is used to prevent nausea and vomiting and to treat diarrhea-predominant irritable bowel syndrome. By blocking serotonin at 5-HT3 receptors, it dampens signals involved in vomiting and in gut motility.
Rifaximin is a semisynthetic, broad-spectrum antibiotic of the rifamycin family that is taken by mouth yet is barely absorbed from the gastrointestinal tract. Because it concentrates within the intestinal lumen while leaving blood levels negligible, it acts almost entirely on gut bacteria. It is used to prevent recurrent hepatic encephalopathy, to treat travelers' diarrhea caused by noninvasive strains of Escherichia coli, and to relieve diarrhea-predominant irritable bowel syndrome, and it is marketed chiefly under the brand name Xifaxan.
Voglibose is an oral antidiabetic medication of the alpha-glucosidase inhibitor class, used to control the rise in blood glucose that follows meals in people with type 2 diabetes. It works within the small intestine by slowing the digestion of complex carbohydrates, which blunts the post-meal glucose peak rather than stimulating insulin. Developed in Japan and introduced there in the 1990s, it is used mainly in parts of Asia and belongs to the same class as acarbose and miglitol.